Boundless Bio’s plans to develop a new class of cancer therapies targeting DNA found outside the nucleus of malignant cells have been boosted by a $100 million fundraising
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.